Axsome Therapeutics, Inc.
NASDAQ:AXSMBiotechnology
+$0.25 today
- Market cap
- $7.05B
- Beta
- 0.60
- P/E (TTM)
- -68.6
- EPS (TTM)
- -$3.68
Volume 0.74M
Average 0.72M
AXSM Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Axsome Therapeutics, Inc.NASDAQ: AXSM
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 5.6% from a year ago
Cash & equivalents stood at $319.85M at the end of Q2 FY2026, up 5.6% from a year earlier and up 4.8% from the prior quarter. Over 3 fiscal years it compounded at +17.2% a year.
Context
- Cash & equivalents amounted to 42.0% of total assets at the end of Q2 FY2026, down 5.4 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +5.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 322.93M USD
- Year-over-year change
- +2.4%
- 4-year CAGR
- +39.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 322.93M | +2.4% |
| FY2024 | 2024-12-31 | 315.35M | -18.3% |
| FY2023 | 2023-12-31 | 386.19M | +92.3% |
| FY2022 | 2022-12-31 | 200.84M | +132.3% |
| FY2021 | 2021-12-31 | 86.47M | — |
Cash & Equivalents vs competitors
How AXSM compares with its peers on the latest reported figures
- AXSM's Jun 2026 cash & equivalents of $319.85M is the 4th highest of the 11 companies compared; the peer median is $190.74M.
- Its year-over-year change of +5.6% is the 10th highest of 11, against a peer median of +39.1%.
- Cash & equivalents amounts to 42.0% of total assets for AXSM, versus a peer median of 17.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $2.04B | +64.7% | +16.4% | 17.0% | |
| Sep 2026 | $641.5M | +88.6% | +39.5% | 11.4% | |
| Sep 2026 | $361.85M | +142.0% | +79.7% | 27.6% | |
| Jun 2026 | $319.85M | +5.6% | +17.2% | 42.0% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $241.15M | +1108.2% | +22.0% | 22.4% |
| Jun 2026 | $201.53M | +42.7% | -2.0% | 17.4% | |
| Jun 2026 | $179.95M | +24.4% | +11.3% | 12.6% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $147.07M | +15.9% | -8.8% | 95.6% |
| Dec 2025 | $131.75M | +9.1% | -11.7% | 99.1% | |
| Sep 2026 | $82.56M | -21.0% | +51.5% | 6.9% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $78.06M | +35.5% | +19.1% | 15.7% |
| Peer median (excluding AXSM) | $190.74M | +39.1% | +17.8% | 17.2% | |
Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 86.47M | 200.84M | 386.19M | 315.35M | 322.93M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 37.7M | 94.82M | 142M | 224.46M |
| Inventory | 0 | 4.32M | 15.14M | 15.73M | 27.94M |
| Other Current Assets | 0 | 2.78M | 8.12M | 11.98M | 13.65M |
| Total Current Assets | 86.52M | 245.64M | 504.26M | 485.06M | 588.99M |
| Property, Plant & Equipment (Net) | 944.01K | 1.14M | 7.62M | 5.97M | 20.86M |
| Goodwill | 0 | 10.31M | 12.04M | 12.04M | 12.04M |
| Intangible Assets | 0 | 59.66M | 53.29M | 46.89M | 40.52M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 322.91K | 14.72M | 11.03M | 18.53M | 27.4M |
| Total Non-current Assets | 1.27M | 85.83M | 83.97M | 83.43M | 100.82M |
| Total Assets | 87.79M | 331.48M | 588.24M | 568.5M | 689.81M |
| Account Payables | 13.15M | 38.61M | 40.68M | 72M | 65.54M |
| Short-term Debt | 0 | 0 | 0 | 0 | 72.98M |
| Tax Payables | 0 | 0 | 0 | 960K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.05M | 17.18M | 76.45M | 36.51M | 203.28M |
| Total Current Liabilities | 23.07M | 96.56M | 138.85M | 230.1M | 378.84M |
| Long-term Debt | 49.09M | 94.26M | 178.07M | 180.71M | 140.93M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 31.1M | 73.3M | 91.68M | 54.36M |
| Total Non-current Liabilities | 49.09M | 125.36M | 258.41M | 281.38M | 222.67M |
| Total Liabilities | 72.15M | 221.92M | 397.26M | 511.48M | 601.51M |
| Common Stock | 3.78K | 4K | 5K | 5K | 5K |
| Retained Earnings | (409.2M) | (596.33M) | (835.57M) | (1.12B) | (1.31B) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | (0) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 15.63M | 109.56M | 190.98M | 57.02M | 88.3M |
| Total Debt | 49.71M | 94.68M | 186.37M | 192.96M | 241.3M |
| Net Debt | (36.76M) | (106.16M) | (199.82M) | (122.4M) | (81.64M) |
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Intrinsic Alpha fair value
Locked
Current Price
$134.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.